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Pseudobulbar Affect (PBA) is an affect disinhibition syndrome
characterized by uncontrollable, exaggerated, and often in-
appropriate outbursts of crying or laughing (Schiffer and Pope,
2005). It has been associated with disruption or damage to neural
systems that modulate voluntary and involuntary emotional ex-
pression (Wortzel et al., 2008; Parvizi et al., 2009; Lauterbach
et al., 2013). PBA has been identiﬁed in patients with a multitude
of neurological disorders, including traumatic brain injury (TBI),
amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke,
and Alzheimer's disease (Moore et al., 1997; Schiffer and Pope,
2005; Wortzel et al., 2008; Parvizi et al., 2009; Colamonico et al.,
2012). TBI is common in military service members deployed in
support of Operation Enduring Freedom, Operation Iraqi Freedom,
and Operation New Dawn (OEF/OIF/OND), occurring in 10–23% of
returning Veterans; the majority of TBI injuries are mild in severityx.doi.org/10.1016/j.jad.2015.10.003
27/Published by Elsevier B.V. This is an open access article under the CC BY-NC
espondence to: GRECC/TRACTS 182 (JP), VA Boston Healthcare System, 150
untington Ave, Boston, MA 02130, United States. Fax: þ1 857 364 4544.
ail address: James.Rudolph@va.gov (J.L. Rudolph).(Hoge et al., 2008; Terrio et al., 2009; Cifu et al., 2013). In a survey
that formed the basis for the present study, we identiﬁed PBA
symptoms in 70% (n¼513) of OEF/OIF/OND Veteran respondents
who screened positive for TBI (Fonda et al., 2015).
TBI represents a well-recognized threat to mental well-being
and health of Veterans. Veterans with TBI are more prone to pain
syndromes, sleep disorders, and other mental health conditions,
particularly posttraumatic stress disorder (PTSD) and depression
(Lippa et al., 2015). PBA may further add to the mental health
burden (Fonda et al., 2015). Additionally, Veterans with co-morbid
TBI, PTSD, and depression reported substantially worse function-
ing compared to Veterans with single or pairwise combinations of
these conditions (Lippa SM et al., 2015).
PTSD occurs in 12–30% of OEF/OIF/OND service members and
Veterans (Seal et al., 2009; Thomas et al., 2010; Higgins et al.,
2014). The co-occurrence of TBI and PTSD is much more common
than TBI alone (Lippa SM et al., 2015), and PTSD is more prevalent
and severe among Veterans who sustain a TBI (Hoge et al., 2008;
Schneiderman et al., 2008). Because PTSD affects some of the same
neural systems as traumatic brain injury (TBI) (Stein and McAll-
ister, 2009), it is possible that the co-occurrence of TBI with PTSD-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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within the Veteran population, the potential inﬂuence of comorbid
PTSD must be considered.
The purpose of this study was to examine the relationship of
PBA symptom frequency and severity to health-related quality of
life and health system costs in Veterans with conﬁrmed TBI,
stratiﬁed by PTSD diagnosis. We hypothesized that increased PBA
symptoms would be associated with reduced quality of life and
increased medical costs in Veterans with TBI, and that these effects
would be present irrespective of comorbid PTSD. We identiﬁed
patients with TBI based on the Veterans Administration (VA) TBI
electronic screening mechanism and surveyed patients with
known TBI to assess quality of life and PBA symptoms. Clinical
characteristics and healthcare utilization and cost were obtained
from the Veterans Health Administration (VHA) electronic medical
records.2. Methods
2.1. Study population
Our study population consisted of OEF/OIF/OND Veterans in the
New England region (VISN-1) who had a conﬁrmed deployment-
related TBI on the VHA comprehensive TBI evaluation between
April 2007 and April 2013. Clinical and healthcare utilization re-
cords and VHA electronic medical records, including inpatient
hospitalization admissions and clinic visits, were linked for qua-
lifying Veterans for ﬁscal year 2012 (the study period). We ex-
cluded Veterans if they had a prior diagnosis of bipolar disorder,
schizophrenia, or other major psychiatric disorder recorded in the
VA medical record. Veterans with trauma-related hallucinations
were retained in the study.
2.2. Procedure
Four thousand two hundred and eighty two (4282) Veterans in
our study population who had a positive TBI screen were mailed a
packet that included a cover letter, a survey, and a pre-addressed,
postage-paid return envelope. Our methods have been previously
described (Fonda et al., 2015). Brieﬂy, the patient survey consisted
of the Center for Neurologic Study-Lability Scale (CNS-LS), a seven-
item instrument that assesses the frequency and severity of in-
voluntary or excessive laughing and crying symptoms (Moore
et al., 1997), and the EuroQol – Five Dimensions – Five Levels (EQ-
5D-5L) (Rabin et al., 2011), a ﬁve-item survey questionnaire that
assesses health-related quality of life. Among 3954 Veterans (92%)
with accurate mailing addresses, 758 (19%) completed the survey.
Among these, 210 with clinically conﬁrmed TBI made up the study
population. A previous report of this sample showed that, com-
pared to survey non-respondents, respondents (n¼758) were
more likely to be older, white, married, and college graduates, and
to have a higher prevalence of depression, prescriptions for de-
pression, and arthropathy related pain (Fonda et al., 2015). Re-
spondents were similar to non-respondents for all other comorbid
conditions and biomedical characteristics, including PTSD, anxiety
disorders, substance abuse, and headaches/migraines. Baseline
demographic and clinical characteristics and healthcare utilization
and cost were obtained from the VHA electronic medical records.
Outpatient visits and hospitalizations, including diagnosis codes,
were extracted from the National Patient Care Database (NPCD).
Pharmacy and cost data were extracted from the VA Decision
Support System (DSS). The survey data were linked to the VA ﬁles
using a unique identiﬁer. The survey cover letter included all
elements of informed consent, and completion and return of thequestionnaire was considered implied consent. All procedures
were approved by the VA Boston Institutional Review Board.3. Measures
3.1. PBA symptom frequency/severity
We assessed the presence of PBA symptoms using the CNS-LS.
The seven-item CNS-LS is a quantitative measure of the frequency
and severity of PBA symptoms (range 7–35; higher is worse
symptoms) (Moore et al., 1997; Smith et al., 2004). In validation
studies, a score of Z13 best predicted a physician diagnosis of PBA
in patients with ALS (Moore et al., 1997) and a score Z17 best
predicted a physician diagnosis of PBA in patients with MS (Smith
et al., 2004). For this analysis, PBA symptom frequency/severity
was categorized as: low (CNS-LS o13), mild (CNS-LS 13–20), and
moderate-severe (CNS-LS Z21) (Moore et al., 1997; Colamonico
et al., 2012; Brooks et al., 2013).
3.2. Prescription medications
We determined use of medication based on having at least one
prescription ﬁlled during ﬁscal year 2012. Medication classes
evaluated included antidepressants, opioids, sedative/hypnotics,
antiepileptics, antilipemic agents, and antihypertensives.
3.3. Comorbid conditions
The presence of a current mental health disorder, including
major depressive disorder, PTSD, anxiety disorders, and alcohol
and substance abuse disorders, as well as pain conditions were
determined using International Classiﬁcation of Diseases, Ninth
Revision (ICD-9) diagnostic codes. We considered a diagnosis to be
current if the Veteran had one or more diagnosis codes or received
a prescription for an agent to treat the conditions of interest
during ﬁscal year 2012.
3.4. Health-Related Quality of Life
We measured health-related quality of life using the EQ-5D-5L
questionnaire, which is an international, standardized, generic
measure of health status developed by the EuroQol Group (Rabin
et al., 2011). The EQ-5D-5L is a two-part instrument consisting of
ﬁve health status dimensions (i.e., mobility, self-care, usual activ-
ities, pain/discomfort, and anxiety/depression) and a visual analog
scale (VAS). Each health status dimension is rated using a ﬁve-
level scale (range 1–5, with 1¼no problems and 5¼extreme
problems/inability to perform activity). The information from the
dimensions was also combined into an EQ-5D index score using
weights from United States standard population values (Rabin
et al., 2011) (range 0–1, lower is worse). The VAS represents the
self-reported health status of the Veteran (range 0–100, lower
scores indicate poorer health status). We calculated the mean and
standard deviation (SD) for the VAS and index scores.
3.5. Healthcare utilization and cost
Healthcare utilization was captured by the unique number of
claims, including inpatient hospitalization admissions and clinic
visits, for each Veteran during ﬁscal year 2012. We calculated the
median number of claims and the interquartile range (IQR). Vari-
able direct costs, which include the cost of supplies and labor
based on the volume of services, were chosen as opposed to total
costs because the VA has signiﬁcant ﬁxed costs that are unrelated
to the cost directly attributable to patient care (i.e., research
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were assigned a zero variable direct cost. We calculated de-
scriptive statistics for the variable direct costs, including mean, SD,
median, and IQR.4. Statistical analyses
We summarized the demographic and clinical characteristics
for the sample, both overall and stratiﬁed by PBA symptom fre-
quency/severity. For categorical variables, statistical signiﬁcance of
differences between groups was determined using Fischer's exact
test (α¼0.05).
The remaining analyses were stratiﬁed by PTSD diagnosis to
examine the effect(s) of TBI alone versus TBI with co-occurring
PTSD. EQ-5D-5L health status was determined for the overall
health scores and each of the ﬁve dimensions. For categorical
variables, we tested statistical signiﬁcance between strata using
the Fisher's exact test. Analysis of variance (ANOVA) was used to
determine if there was a signiﬁcant interaction between theTable 1
Baseline demographic and clinical characteristics by PBA symptom frequency/severity.
Total PBA sympto
o13
(n¼210) (n¼57)
Age (mean, SD) 37.79 (9.78) 36.85 (9.18)
Males 201 (95.7%) 57 (100%)
Race
White 170 (80.9%) 46 (80.7%
Other or unknown 40 (19.1%) 11 (19.3%
Marital status
Single 70 (33.3%) 18 (31.6%)
Married 103 (49.1%) 33 (57.9%)
Divorced, separated, other 37 (17.6%) 6 (10.5%
Education
College graduate or more 28 (13.3%) 10 (17.5%)
Some college / technical training 70 (33.3%) 20 (35.1%
High school education or less 112 (53.3%) 27 (47.4%)
Mental health disorders
Major depression 68 (32.4%) 13 (22.8%
PTSD 112 (53.3%) 21 (36.8%
Anxiety disorders 36 (17.1%) 2 (3.5%)
Substance abuse/dependence 32 (15.2%) 8 (14.0%
Prescription medication
Antidepressants 87 (41.4%) 14 (24.6%
Opioids 38 (18.1%) 5 (8.8%)
Sedative/hypnotics 40 (19.1%) 4 (7.0%)
Antiepileptics 46 (21.9%) 11 (19.3%
Comorbidities
Hyperlipidemiab 44 (21.0%) 9 (15.8%
Hypertensionc 33 (15.7%) 8 (14.0%
Pain conditions 113 (53.8%) 28 (49.1%
Osteoarthritis 21 (10.0%) 4 (7.0%)
Back/neck pain 70 (33.3%) 14 (24.6%
Other arthropathies 79 (37.6%) 22 (38.6%
Headache/migraine 44 (20.9%) 11 (19.3%
Abbreviations: CNS-LS, Center for Neurologic Study-Lability Scale; PBA, Pseudobulbar A
This table presents the frequency and column percentage, unless otherwise noted.
a p-Value across PBA symptom frequency/severity categories from ANOVA for age o
b Hyperlipidemia: ICD-9 diagnostic code or current antilipemic agent.
c Hypertension: ICD-9 diagnostic code or current antihypertensive agent (alpha, bet
and thiazide diuretics).severities of PBA symptoms (low, mild, moderate- severe) and
PTSD diagnosis (no, yes) for the overall health status measures,
with a separate model for VAS and EQ-5D-5L index scores. For the
health status dimensions, we calculated the mean and SD of the
responses (1–5 for each dimension), as well as the frequency and
percent of Veterans with moderate or worse impairment (mod-
erate-severe problem or unable to perform; 3 or greater on 1–5
scale). Log-linear models were used to identify signiﬁcant inter-
actions between the severity of PBA symptoms (low, mild, mod-
erate-severe) and PTSD diagnosis, and the EQ-5D-5L dimension
responses (dichotomized to less than moderate and moderate or
greater impairment) (Agresti, 2002).
Analyses were conducted using SAS (version 9.3) software and
R (version 3.0.0).5. Results
Our study population (n¼210) was predominantly male (95%),
with an average age of 37.8 years (SD¼9.78). Based on reportedm frequency/severity (CNS-LS) p-Valuea
13–20 Z21
(n¼93) (n¼60)
37.87 (9.54) 38.57 (10.75) 0.6353
86 (92.5%) 58 (96.7%) 0.0882
) 79 (84.9%) 45 (75.0%) 0.3147
) 14 (15.1%) 15 (25.0%)
36 (38.7%) 16 (26.7%) 0.1710
41 (44.1%) 29 (48.3%)
) 16 (17.2%) 15 (25.0%)
14 (15.0%) 4 (6.7%) 0.2470
) 26 (28.0%) 24 (40.0%)
53 (57.0%) 32 (53.3%)
) 31 (33.3%) 24 (40.0%) 0.1336
) 49 (52.7%) 42 (70.0%) 0.0015
20 (21.5%) 14 (23.3%) 0.0021
) 13 (14.0%) 11 (18.3%) 0.7327
) 37 (39.8%) 36 (60.0%) 0.0004
18 (19.4%) 15 (25.0%) 0.0574
21 (22.6%) 15 (25.0%) 0.0160
) 14 (15.1%) 21 (35.0%) 0.0142
) 22 (23.7%) 13 (21.7%) 0.5430
) 17 (18.3%) 8 (13.3%) 0.7160
) 47 (50.5%) 38 (63.3%) 0.2190
8 (8.6%) 9 (15.0%) 0.3419
) 31 (33.3%) 25 (41.7%) 0.1521
) 30 (32.3%) 27 (45.0%) 0.2787
) 22 (23.7%) 11 (18.3%) 0.7289
ffect; PTSD, posttraumatic stress disorder; SD, standard deviation.
r Fisher’s exact chi-square all others.
a and calcium channel blockers; ACE inhibitor; angiotensin II receptor antagonists;
Table 2
Quality of life by current PTSD diagnosis and PBA symptom frequency/severity.
CNS-LS CNS-LS CNS-LS p-Value
o13 13–20 Z21
(n¼57) (n¼93) (n¼60)
Overall health
status
VAS score 68.41 (16.52) 62.75 (18.63) 53.92 (17.80) o0.0001
EQ-5D index score 0.69 (0.16) 0.63 (0.18) 0.53 (0.14) o0.0001
Quality of life
domains
Mobility
Functioning 1.82 (0.76) 1.97 (0.87) 2.23 (0.81) 0.0248
Moderate or
greater
impairment
12 (21.1%) 25 (27.2%) 22 (36.7%) 0.0601
Self-care
Functioning 1.21 (0.45) 1.48 (0.79) 1.58 (0.75) 0.0150
Moderate or
greater
impairment
1 (1.8%) 10 (10.9%) 5 (8.5%) 0.1802
Usual activities
Functioning 2.23 (0.85) 2.50 (0.97) 2.95 (0.96) 0.0002
Moderate or
greater
impairment
19 (33.3%) 41 (44.6%) 41 (68.3%) 0.0001
Pain or discomfort
Functioning 2.68 (0.97) 2.95 (0.94) 3.30 (0.85) 0.0017
Moderate or
greater
impairment
33 (57.9%) 65 (70.7%) 50 (83.3%) 0.0025
Anxiety or
depression
Functioning 2.67 (1.15) 3.23 (1.01) 3.75 (0.79) o0.0001
Moderate or
greater
impairment
29 (50.9%) 75 (81.5%) 56 (93.3%) o0.0001
Abbreviations: CNS-LS, Center for Neurologic Study-Lability Scale; EQ-5D, EuroQol
– Five Dimensions; VAS, visual analog scale.
Note: the mean (SD) were calculated for the VAS score, EQ-5D index score, and
functioning total for each quality of life domain.
VAS score ranged from 0–100. EQ-5D index score ranged from 0–1 and was com-
puted using weights from the United States standard population values.
Moderate or greater impairment was deﬁned as a functioning score of 3 or greater
for each health status domain.
Table 3
PBA severity and variable direct costs in Veterans with TBI.
n Median # of
claims (IQR)
Average cost
(SD)
Median cost
(IQR)
Total costs
CNS o13 57 11 (0, 29) $2825 $1401
($5172) ($0, $3179)
CNS 13–20 93 13 (4, 29) $3721 $1462
($6826) ($444, $3903)
CNS Z21 60 22 (5, 75) $5718 $2285
($7233) ($605, $10,050)
Outpatient costs
CNS o13 57 11 (0, 29) $2146 $1316
($3031) ($0, $3179)
CNS 13–20 93 13 (4, 29) $3480 $1462
($6114) ($444, $3903)
CNS Z21 60 22 (5, 74) $4571 $2084
($5195) ($605, $7458)
Abbreviations: CNS, Center for Neurologic Study; IQR, interquartile range; SD,
standard deviation.
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toms, 44.3% (n¼93) had mild PBA symptoms, and 27.6% (n¼60)
had moderate-severe PBA symptoms (Table 1). Age, sex, education
level, and diagnosed physical comorbidities, including pain con-
ditions, were not statistically different across the PBA symptom
frequency/severity categories. The overall prevalence of a PTSD
diagnosis was 53%, and signiﬁcantly increased with PBA symptom
frequency/severity: low (n¼21, 36.8%), mild (n¼49, 52.7%), and
moderate-severe (n¼42, 70%) (p¼0.0015). Similarly, anxiety dis-
order (17% overall) increased signiﬁcantly with PBA symptom
frequency/severity: low (n¼2, 3.5%), mild (n¼20, 21.5%), and
moderate-severe (n¼14, 23%) (p¼0.0021). Major depression in-
creased similarly, but not signiﬁcantly. The prevalence of pre-
scription medications for mental health issues followed the same
increasing trend, with all but opioids showing statistically sig-
niﬁcant differences across PBA symptom frequency/severity
categories.
Overall health status decreased with increasing PBA symptom
frequency/severity, as shown in Table 2. ANOVA revealed a main
effect of PBA symptom frequency/severity on mean EQ-5D-5L VAS
(F¼9.73; df¼2, po0.0001) and index scores (F¼13.84; df¼2,
po0.0001) for the entire population. However, there was no sta-
tistically signiﬁcant interaction between PBA symptom frequency/
severity and PTSD diagnosis for either mean EQ-5D-5L VAS(F¼0.20; df¼2, p¼0.820) or EQ-5D-5L index scores (F¼1.44; df¼
2, p¼0.239). The log-linear models for the ﬁve health status di-
mensions showed signiﬁcant associations with PBA symptoms
(mild/moderate-severe vs. low) independent of PTSD status in
three dimensions: pain/discomfort (odds ratio [OR]¼3.6; 95%
conﬁdence interval [CI]: 1.5,8.6), usual activities (OR¼3.5; 95% CI:
1.6, 7.8), and anxiety/depression (OR¼13.5; 95%CI: 4.3, 42.2).
Tables 3 and 4 describe the healthcare utilization and variable
direct cost outcomes according to PBA symptom frequency/se-
verity and the presence or absence of PTSD. Mean total and out-
patient costs were highest in those with moderate-severe PBA
symptoms and PTSD. Mean total health costs in those with mild
and moderate-severe PBA symptoms were 32% and 102% higher,
respectively, than in those with low PBA symptom (Table 3), al-
though SDs were large compared to the mean values. In those with
comorbid PTSD, costs were only modestly higher (8.6%) in those
with moderate-severe PBA symptoms compared to low PBA
symptoms. Costs for those with PTSD were three- to six-fold
higher within PBA symptom frequency/severity categories com-
pared to those without PTSD (Table 4). Mental health costs made
up about 20–30% of outpatient healthcare costs in ﬁve of the six
PBA by PTSD strata (data not shown); however for the stratum
with “moderate-severe PBA symptoms and no PTSD,” mental
health costs made up only 7% of outpatient costs. This stratumwas
very small (n¼4) and the relative SD was large (SD/mean¼2.95).
Regardless of PTSD diagnosis, the relative increases in costs were
larger between the low and mild PBA symptom groups than be-
tween the mild and moderate-severe PBA symptom groups.6. Discussion
This study of Veterans with TBI, who were surveyed about PBA
symptoms and quality of life, found that the severity of PBA
symptoms was associated with presence of a PTSD diagnosis, in-
creased use of prescription medications, and decreased quality of
life across a number of dimensions. PBA symptoms were asso-
ciated with decreased quality of life, particularly in the pain/dis-
comfort, usual activities, and anxiety/depression dimensions, in-
dependent of PTSD diagnosis. Additionally, the mean total out-
patient costs increased with increasing PBA symptoms. These re-
sults suggest that in patients with TBI, an assessment of PBA
symptoms may identify patients who report lower quality of life
and accrue more healthcare costs.
The two metrics of overall health-related quality of life (VAS
and EQ-5D) declined signiﬁcantly as a function of PBA symptom
Table 4
Quality of life and variable direct costs stratiﬁed by current PTSD diagnosis and PBA
severity.
No PTSD PTSD
CNS-LS CNS-LS CNS-LS CNS-LS CNS-LS CNS-LS
o13 13–20 Z21 o13 13–20 Z21
(n¼36) (n¼44) (n¼18) (n¼21) (n¼49) (n¼42)
Overall
health
status
VAS score* 70.06
(15.45)
65.57
(18.14)
59.94
(15.03)
65.45
(18.32)
60.22
(18.88)
51.27
(18.44)
EQ-5D In-
dex
score**
0.74
(0.12)
0.66
(0.17)
0.62
(0.11)
0.60
(0.19)
0.60
(0.19)
0.49
(0.14)
Total variable direct costs
Mean (SD) $957 $1450 $1629 $6028 $5760 $7470
($1276) ($3870) ($3298) ($7416) ($8180) ($7764)
Median
(IQR)
$349 $323 $369 $3173 $2589 $3959
($0,
$1462)
($0,
$1452)
($0,
$1816)
($1953,
$7625)
($1426,
$5771)
($1326, $
12,229)
Median #
Claims
(IQR)
1 (0, 12) 4 (0, 13) 3 (0, 16) 33 (20,
43)
25 (12,
52)
34 (14,
82)
Outpatient variable direct costs
Mean (SD) $899 $1450 $1629 $4283 $5302 $5832
($1240) ($3870) ($3298) ($3929) ($7145) ($5375)
Median
(IQR)
$349 $323 $369 $3173 $2589 $3750
($0,
$1419)
($0,
$1452)
($0,
$1816)
($1953,
$4607)
($1426,
$5771)
($1326,
$9823)
Median #
Claims
(IQR)
1 (0, 12) 4 (0, 13) 3 (0, 16) 33 (20,
43)
25 (12,
52)
34 (13,
81)
Abbreviations: CNS-LS, Center for Neurologic Study-Lability Scale; EQ-5D, EuroQol
– Five Dimensions; IQR, interquartile range; PTSD, posttraumatic stress disorder;
VAS, visual analog scale.
Note: the number of claims was calculated as the unique number of clinic visits or
inpatient hospitalizations. This table displays the median and interquartile range
for the number of claims for each speciﬁc category.
* p¼0.012 for PTSD group and p40.05 for No PTSD group by ANOVA.
** p¼0.0063 for PTSD group and p¼0.0049 for No PTSD group by ANOVA.
a The quality of life measure rated the response to the question, “How has your
neurological condition affected your quality of life?” on a horizontal, 11-point in-
teger scale ranging from 0 (not at all) on the left to 10 (strongly affected) on the
right.
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PTSD. This suggests that the involuntary expression of emotion
characteristic of PBA symptoms following TBI may not be an ex-
pression of emotional disinhibition that can be characteristic of
PTSD, but rather that PBA symptoms may be an independent
factor of the decline in quality of life. This adds to the complexity
of the clinical presentation of these Veterans, and our analysis of
the quality of life dimensions provides further insight into the
underlying mental health challenges.
Our ﬁndings of decreasing quality of life in the anxiety/de-
pression, pain/discomfort, and usual activities dimensions (in-
dependent of PTSD) underscore the functional challenges patients
with increasing PBA symptoms confront. The association of in-
creasing EQ-5D anxiety/depression scores with increasing PBA
symptoms is consistent with previous studies that reported in-
creased depression (Phuong et al., 2009; Colamonico et al., 2012)
and/or anxiety (Tateno et al., 2004; Colamonico et al., 2012) in
subjects reporting PBA symptoms. While not assessing PBA spe-
ciﬁcally, our prior work (Lippa et al., 2015) found that pain/dis-
comfort was related to TBI, perhaps due to the high prevalence of
blast injuries in the OEF/OIF/OND cohort that can affect multiple
biological systems (i.e., central nervous system, pulmonary, mus-
culoskeletal). The association of the increasing EQ-5D usual ac-
tivity scores (poorer function) with increasing PBA symptoms is
consistent with previous studies that reported signiﬁcantly poorerfunction on activities of daily living scales (Colamonico et al.,
2012), social functioning scales (Tateno et al., 2004), and a general
quality of life measure.a (Brooks et al., 2013)
Lastly, we found that patients with the most severe PBA
symptoms accrued higher costs, in particular, outpatient costs.
While there was an overall three- to four-fold increase in costs for
those with PTSD, there was a consistent increase in outpatient
costs associated with increasing PBA symptoms. Past work has
found that treatment decisions were based on the more commonly
recognized and diagnosed comorbid mental health conditions ra-
ther than recognized PBA even when PBA is present, and perhaps,
misdiagnosed (Arciniegas et al., 2005, Engelman et al., 2014).
While our data suggest that there may be an association be-
tween PBA severity and TBI severity (not reported), we do not feel
that the current data can support this claim deﬁnitively, as our
instrument identiﬁed only a handful of participants with moderate
or severe TBI (n¼22). Further exploration of this possibility is
warranted in future investigations.
This study has strengths that should be recognized. First, the
study included patients with known TBI, and particularly those
with mild TBI. The population studied had more mental health
conditions than the general US population of similar age. We
found prevalences of diagnosed major depression, PTSD, and an-
xiety disorders of 32.4%, 53.3%, and 17.1%, respectively. In the Na-
tional Comorbidity Survey Replication, reported prevalences of
major depression, PTSD, and anxiety in 30- to 44-year-olds were
19.8%, 8.2%, and 6.8%, respectively (Kessler et al., 2005). The study
population had access to and was receiving mental health treat-
ments as demonstrated by VA cost, claims, and pharmacy data,
which developed a comprehensive picture of healthcare utilization
by these Veterans.
There are also limitations to this work. First, the study utilized a
home survey tool to identify PBA symptoms. As a result, we were
unable to determine the circumstances of the survey completion.
While this PBA symptom scale has good sensitivity and speciﬁcity
relative to physician diagnosis of PBA in persons with ALS and MS,
its diagnostic utility has not been speciﬁcally validated in TBI.
Additionally, we utilized claims data to determine those with and
without PTSD. Clearly, the work would have beneﬁtted from a
clinical diagnosis of PBA and documented diagnosis of PTSD. Ad-
ditionally, the Veteran population tends to be predominantly male,
and in this case, younger. In the current sample, there were only
nine females, which precluded our ability to examine gender dif-
ferences in the incidence of PBA following TBI. Our study sample
was deﬁned to determine whether PBA symptoms are present in a
Veteran cohort with a history of military TBI. The Veteran cohort is
predominantly male; more so among those exposed to combat
who would have heightened risk for TBI, and this was reﬂected in
our ﬁnal sample. Only about 8% of the Veteran population is fe-
male and females represent less than 4% of Veterans who have
served in war zones (Boyd et al., 2013). A subsequent study that
oversamples women with TBI would be required to address gen-
der differences in PBA following TBI.
The current, cross sectional data revealed high co-prevalence of
TBI, PBA and PTSD. While we presume the progression begins with
TBI (and PBA by deﬁnition occurs as a consequence of neurologic
injury), we cannot conﬁrm that with these data. Understanding
the relationship(s) between physical trauma to the brain and the
development of psychological sequelae of trauma is currently a
focus of much research. Advancement of our knowledge of these
relationships will require longitudinal studies that can track the
J.L. Rudolph et al. / Journal of Affective Disorders 190 (2016) 150–155 155progression and development of illness overtime. However, this
study was able to minimize potential retrospective reporting bia-
ses common to cross-sectional studies by obtaining clinical and
TBI information from electronic medical records and standardized
TBI reports. Finally, this study limited the sample to OEF/OIF/OND
Veterans who received care at a VA in the New England region.
Nevertheless, this sample closely resembles the demographic
characteristics of a national cohort of younger US Veterans and
survey non-respondents (Eber et al., 2013; Fonda et al., 2015).
Thus, results could be generalized to a national sample of OEF/OIF/
OND Veterans with deployment-related TBI.Conclusion
This study examined the relationship of PBA symptom fre-
quency/severity to health-related quality of life and outpatient
costs in OEF/OIF/OND Veterans in the New England region with
mild TBI. We found that severe PBA symptoms were associated
with reduced quality of life and increased outpatient medical costs
in those with and without comorbid PTSD.
Patients with TBI should be assessed for the presence of PBA
symptoms. The larger survey that preceded this work, (Fonda
et al., 2015), found that simply asking a single question about the
presence of involuntary or exaggerated episodes of laughing or
crying may be an effective means of determining the need for
further assessment. Veterans who screen positive for PBA symp-
toms using this single question could undergo a more thorough
clinical evaluation, including the use of the CNS-LS to evaluate the
frequency and severity the PBA symptoms.Funding/support
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